pERK-mediated IL8 secretion can enhance the migration, invasion, and cisplatin resistance of CD10-positive oral cancer cells

BMC Cancer. 2021 Dec 1;21(1):1283. doi: 10.1186/s12885-021-09025-7.

Abstract

Background: Cancer stem cells (CSCs) drive tumor initiation and progression and participate in tumor chemoresistance. We recently discovered that oral squamous cell carcinoma (OSCC) cells that highly express CD10 (CD10H cells) present cancer stem cells (CSC)-associated characteristics, which, in turn, affect the tumor growth, epithelial-mesenchymal transition (EMT), and resistance to cisplatin. In this study, we further investigated this mechanism in vitro and in vivo. We hypothesized that IL8 might regulate migration, invasion, and cisplatin resistance of CD10-positive oral cancer cells through the ERK pathway.

Methods: CD10 MicroBead Kit was used to select HN6 cells with high and low expression of CD10. The target protein IL8 was screened via protein chip assay. Lentiviral transduction and specific inhibitor were applied to investigate the signaling pathway. Real-time PCR, Western blot, and immunohistochemistry were used to analyze the mRNA and protein expression; transwell assay, spheroid formation assay, and cell viability assay were used to study the cell biological behavior in vitro; xenograft animal model was used to evaluate the tumor formation rate in vivo.

Results: Overexpression of CD10 promoted CSC-related genes expression and enhanced migration, invasion, spheroid formation, and chemoresistance in HN6 cells. Moreover, the overexpression of IL8 was detected in OSCC tumor tissue and cell lines (HN6 and CAL27) overexpressing CD10. IL8 secreted by CD10H HN6 promoted migration and invasion and restored tumor chemosensitivity via the p-ERK signaling pathway, while the inhibition of IL8 increased the chemosensitivity to cisplatin.

Conclusions: IL8 secretion by CD10 positive cells promotes migration, invasion, and cisplatin resistance of OSCC via the p-ERK signaling pathway.

Keywords: Cisplatin; Drug resistance; IL8, CD10, p-ERK; Oral squamous cell carcinoma.

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use
  • Cell Communication
  • Cell Movement
  • Cisplatin / therapeutic use
  • Drug Resistance, Neoplasm*
  • Female
  • Gene Expression
  • Heterografts
  • Humans
  • Interleukin-8 / antagonists & inhibitors
  • Interleukin-8 / metabolism*
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Mouth Neoplasms / drug therapy
  • Mouth Neoplasms / metabolism*
  • Mouth Neoplasms / pathology
  • Neoplasm Invasiveness
  • Neoplasm Transplantation
  • Neoplastic Stem Cells
  • Neprilysin / metabolism*
  • Signal Transduction
  • Spheroids, Cellular / pathology
  • Squamous Cell Carcinoma of Head and Neck / drug therapy
  • Squamous Cell Carcinoma of Head and Neck / metabolism*
  • Squamous Cell Carcinoma of Head and Neck / pathology
  • eIF-2 Kinase / metabolism*

Substances

  • Antineoplastic Agents
  • Interleukin-8
  • EIF2AK3 protein, human
  • eIF-2 Kinase
  • Neprilysin
  • Cisplatin